Bing Zhao1, Alejandro Rabinstein2, Mohammad H Murad3, Giuseppe Lanzino1, Pietro Panni4, Waleed Brinjikji5. 1. Department of Neurosurgery, Mayo Clinic, Rochester, MN, USA. 2. Department of Neurology, Mayo Clinic, Rochester, MN, USA. 3. Center for Science of Healthcare Delivery, Mayo Clinic, Rochester, MN, USA. 4. San Raffaele University Hospital, Milan, Italy. 5. Department of Radiology, Mayo Clinic, Rochester, MN, USA - bing.zhao@mayo.edu.
Abstract
INTRODUCTION: Poor-grade aneurysmal subarachnoid hemorrhage (aSAH) is associated with high morbidity and mortality. We evaluated trends in outcomes and treatment of poor-grade aSAH and performed a meta-analysis evaluating outcomes by treatment modality. EVIDENCE ACQUISITION: We performed a literature search for studies on surgical and endovascular treatment of poor-grade aSAH. We performed a random effects meta-analysis evaluating long-term good neurological outcome, long-term poor neurological outcome and mortality, comparing rates between endovascular and surgical treatments. We performed a subgroup analysis of outcome by treatment timing relative to the aSAH separating treatment timing into three categories: 1) ultra-early (within 48 hours of aSAH); 2) early (between 48 hours-1 week post-aSAH); and 3) delayed (>1 week post-aSAH). We also evaluated trends in treatment modalities and good neurological outcome. EVIDENCE SYNTHESIS: Eighty-five non-comparative studies with 4506 patients with poor-grade aSAH were included. The proportion of patients receiving endovascular treatment increased from 10.0% to 62.0% between 1990-2000 and 2010-2014. The rate of good neurological outcome increased from 37.0% to 44.0% over this time period. Long-term good neurological outcome was 38% (95% CI=33-43%) in the endovascular group and 39% (95% CI=34-44%) in the surgical group (P=0.74). Mortality rates were higher in the endovascular group compared to the surgical group (41% versus 31%, P=0.01). Overall, patients receiving ultra-early treatment had the highest rates of good neurological outcome (61% compared to 40% for early and 47% for delayed, P<0.01). CONCLUSIONS: Good neurological outcome rates are similar between surgery and endovascular treatment of poor grade aSAH. Ultra-early treatment is associated with improved clinical outcomes.
INTRODUCTION: Poor-grade aneurysmal subarachnoid hemorrhage (aSAH) is associated with high morbidity and mortality. We evaluated trends in outcomes and treatment of poor-grade aSAH and performed a meta-analysis evaluating outcomes by treatment modality. EVIDENCE ACQUISITION: We performed a literature search for studies on surgical and endovascular treatment of poor-grade aSAH. We performed a random effects meta-analysis evaluating long-term good neurological outcome, long-term poor neurological outcome and mortality, comparing rates between endovascular and surgical treatments. We performed a subgroup analysis of outcome by treatment timing relative to the aSAH separating treatment timing into three categories: 1) ultra-early (within 48 hours of aSAH); 2) early (between 48 hours-1 week post-aSAH); and 3) delayed (>1 week post-aSAH). We also evaluated trends in treatment modalities and good neurological outcome. EVIDENCE SYNTHESIS: Eighty-five non-comparative studies with 4506 patients with poor-grade aSAH were included. The proportion of patients receiving endovascular treatment increased from 10.0% to 62.0% between 1990-2000 and 2010-2014. The rate of good neurological outcome increased from 37.0% to 44.0% over this time period. Long-term good neurological outcome was 38% (95% CI=33-43%) in the endovascular group and 39% (95% CI=34-44%) in the surgical group (P=0.74). Mortality rates were higher in the endovascular group compared to the surgical group (41% versus 31%, P=0.01). Overall, patients receiving ultra-early treatment had the highest rates of good neurological outcome (61% compared to 40% for early and 47% for delayed, P<0.01). CONCLUSIONS: Good neurological outcome rates are similar between surgery and endovascular treatment of poor grade aSAH. Ultra-early treatment is associated with improved clinical outcomes.